News

"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...
London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...
GSK plc announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a phase III-ready, potential best-in-class investigational ...
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...
British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...
GSK GSK-1.00 % decrease; red down pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.
Boston Pharmaceuticals licensed the medicine from Novartis in 2020, with GSK now on the hook for success-based milestone payments and tiered royalties to the Swiss drugmaker.
BOSTON, June 9, 2025 – The Renaissance Boston Seaport District recently debuted its stunning new rooms… Scouting America is proud to announce that Bob Rivers, Executive Chair and Chair of the ...